QQ客服 官方微博 反馈留言

	Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
	Kong Lingling; Wang Linlin; Xing Ligang; Yu Jinming
刊名	慢性疾病与转化医学
	2017
卷号	3期号:4页码:221-229
关键词	Non-small cell lung cancer Brain metastases Epidermal growth factor receptor mutation Tyrosine kinase inhibitors Therapeutic outcomes
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4585840
专题	山东大学
作者单位	Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Key Laboratory of Radiation Oncology of
推荐引用方式 GB/T 7714	Kong Lingling,Wang Linlin,Xing Ligang,et al. Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases[J]. 慢性疾病与转化医学,2017,3(4):221-229.
APA	Kong Lingling,Wang Linlin,Xing Ligang,&Yu Jinming.(2017).Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases.慢性疾病与转化医学,3(4),221-229.
MLA	Kong Lingling,et al."Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases".慢性疾病与转化医学 3.4(2017):221-229.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。